Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up
Authors' conclusion
A model based on histological subtype, TPO and NIS expression and TERT promoter mutation, all evaluated on initial surgical material, can predict iodine avidity in thyroid cancer tissue ahead of treatment. This could inform early adaptation with respect to expected treatment effect.
Study context
- Population
- Patients with papillary and poorly differentiated thyroid cancer; surgical specimens (primary tumour and lymph node metastases)
- Participants
- 28 patients
- Outcome
- Quantitative iodine avidity in surgical specimens vs immunohistochemical expression of TSH receptor, TPO, pendrin, NIS and BRAF and TERT promoter mutational status; independent predictors of poor iodine avidity
Main finding
As reported in the abstract
BRAF mutation: lower iodine avidity for lymph node metastases (significant)
18-fold
TERT promoter mutation: lower iodine avidity for lymph node metastases (significant)
10-fold
Correlation of thyroid peroxidase (TPO) expression with iodine avidity (significant)
r = 0.44
Multivariable: tissue localisation, histological subtype, TPO and NIS expression and TERT promoter mutation each independent predictors; variation of iodine avidity explained
68%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →